《高盛認股證牛熊證》藥明連挫2日 部署前宜重新審視條款 留意貼價購11447、高槓杆購25642、遠牛53247
正股表現:藥明(2269)昨日失守60元水平,今早高開後急挫,最低見52.3元的一個半月低位。現報52.95元,跌約7.6%。早前有券商指內地醫企與受上海封城影響的重點企業討論後,認爲首季經營情況正常,次季業務影響可控。
復星(2196)今早表現則較平穩,在31至32元附近上落。現報32.05元,升約0.6%。
資金流向:觀察個股輪證資金流向,本週二及本週三共錄得約180萬元資金流入藥明好倉,並見昨日流入牛證的資金較集中在50元收回區域的產品。上週五及本週二共錄得約60萬元資金流入淡倉後,昨日獲資金轉向沽出。
復星方面,本週二及本週三共錄得約40萬元資金流入認購證。
產品選擇:由於藥明股價急挫,投資者在部署時宜重新審視產品條款,例如可留意貼價條款的選擇以控風險。
投資者如看好藥明,認購證方面的貼價選擇可留意屬長年期的藥明購11447,爲低時間值損耗。高槓杆選擇可留意年期約3個月的藥明購25642。價外選擇可留意年期約4個月的低面值藥明購13710。牛證方面的遠牛選擇可留意藥明牛53247,與現價有約12元收回距離。近牛選擇可留意藥明牛63113。
藥明購11447,行使價60元,2023年02月21日到期,實際槓桿2.5倍,貼價、長年期、低時間值損耗
藥明購25642,行使價66.9元,2022年08月24日到期,實際槓桿4.7倍,高槓杆
藥明購13710,行使價73.38元,2022年08月24日到期,實際槓桿4.9倍,價外、低面值
藥明牛53247,收回價40元,行使價38.5元,換股比率100,實際槓桿3.5倍,相近收回價遠牛中街貨較低
藥明牛63113,收回價50元,行使價48.5元,換股比率100,實際槓桿10.8倍,市場上首三高槓杆之一近牛
投資者如看淡藥明,可留意藥明熊61535,與現價有約28元收回距離。
藥明熊61535,收回價80元,行使價81.5元,換股比率100,實際槓桿1.9倍,相近收回價熊證中槓桿最高
投資者如看好復星,可留意屬長期的低面值復醫購20452。
復醫購20452,行使價42.9元,2022年11月25日到期,實際槓桿3.7倍,長期、低面值
注: 以上數據資料來自高盛認股證牛熊證網站https://www.gswarrants.com.hk/~
重要聲明:
以上資訊由第三方提供,AASTOCKS.com Limited對於任何包含於、經由、連結、下載或從任何與本網站有關服務所獲得之資訊、內容或廣告,不聲明或保證其內容之正確性或可靠性。對於您透過本網站上之廣告、資訊或要約而展示、購買或取得之任何產品、資訊資料,本公司亦不負品質保證之責任。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.